“SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling” (2024) Bangladesh Journal of Pharmacology, 19(2), pp. 52–58. doi:10.3329/bjp.v19i2.72787.